Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
J Infect Dis
; 172(4): 1126-9, 1995 Oct.
Article
em En
| MEDLINE
| ID: mdl-7561195
Cholera vaccine candidate Peru-15 was derived from a Vibrio cholerae O1 El Tor Inaba strain by deleting the cholera toxin genetic element, introducing the gene encoding cholera toxin B subunit into recA, and screening for nonmotility. In a controlled study, Peru-15 (2 x 10(8) cfu) was administered to 11 volunteers. No vaccinee developed diarrhea, and 10 of 11 had > 4-fold rises in vibriocidal antibody titers. One month later, 5 vaccinees and 5 control volunteers were challenged with wild type V. cholerae O1. Four of 5 controls developed diarrhea (mean, 1.9 L). Two Peru-15 vaccinees developed diarrhea, 1 with < 0.3 L and 1 with approximately 1.0 L; this latter volunteer had not developed a significant vibriocidal immune response to vaccination. Peru-15 shows promise as a single-dose, oral cholera vaccine that is safe, immunogenic, and protective.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra Cólera
/
Cólera
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Humans
País/Região como assunto:
America do sul
/
Peru
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos